Clinical Trial Update: A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Mircera given every four weeks to epoetin beta in dialysis patients with anemia due to chronic kidney disease, assessing maintenance of …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)
• NeoRecormon (epoetin beta)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 3 | Status: COMPLETED